REPORTING FOR 2019-08-22 | TODAYISRAEL.COM: With the assistance of the Beat The Market Analyzer software and our own in-house methods, we have ...
Selinexor plus dexamethasone induced objective responses and a significant overall survival among heavily pretreated patients with multiple myeloma, ...
Usa Financial Portformulas Corp decreased its stake in Aes Corp (AES) by 60.26% based on its latest 2019Q1 regulatory filing with the SEC. Usa Financial ...
In an interview with Targeted Oncology, Ruben Mesa, MD, discussed the results from the reanalysis of the JAKARTA-2 trial that led to the approval of fedratinib ...
Strategic Advisors Llc increased its stake in Cvs Health Corp (CVS) by 246.16% based on its latest 2019Q1 regulatory filing with the SEC. Strategic Advisors ...
The The AES Corporation (NYSE:AES) is going down by -1.11% in today's trading session, a fall equivalent to -0.17% of the stock's price from yesterday's market ...
The FDA has granted a New Drug Application for zanubrutinib a priority review for the treatment of patients with mantle cell lymphoma who have previously ...
Comerica Bank grew its stake in AES Corp (NYSE:AES) by 115.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange ...